In order to evaluate the association between CHD1L overexpression and the response to cisplatin-based chemotherapy in NSCLC patients, we further tested CHD1L expression by IHC in a restricted cohort of locally advanced NSCLC treated with cisplatin-based neoadjuvant chemotherapy (n = 30). This evidence concerns the gene CHD1L and non-small cell lung carcinoma.